Ambee Pharmaceuticals PLC (DSE:AMBEEPHA)
Bangladesh
· Delayed Price · Currency is BDT 757.90
-13.50 (-1.75%)
At close: Apr 27, 2026
Ambee Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 183.57 | 230.55 | 219.3 | 198.1 | 180.99 | 98.98 | Upgrade
|
| Revenue Growth (YoY) | -18.88% | 5.13% | 10.71% | 9.45% | 82.86% | -65.31% | Upgrade
|
| Cost of Revenue | 98.33 | 119.16 | 103.14 | 92.53 | 83.62 | 58.27 | Upgrade
|
| Gross Profit | 85.24 | 111.39 | 116.16 | 105.56 | 97.37 | 40.71 | Upgrade
|
| Selling, General & Admin | 79.99 | 104 | 103.75 | 92.39 | 82.51 | 47.99 | Upgrade
|
| Operating Expenses | 79.99 | 104 | 103.75 | 92.39 | 82.51 | 47.99 | Upgrade
|
| Operating Income | 5.25 | 7.39 | 12.41 | 13.17 | 14.86 | -7.28 | Upgrade
|
| Interest Expense | -0.05 | -0.09 | -0.58 | -2.49 | -4.62 | -5 | Upgrade
|
| Interest & Investment Income | 3.6 | - | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0 | -0 | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | 8.8 | 7.3 | 11.83 | 10.68 | 10.23 | -12.28 | Upgrade
|
| Pretax Income | 8.8 | 7.3 | 11.83 | 10.68 | 10.23 | -12.28 | Upgrade
|
| Income Tax Expense | 2.2 | 1.99 | 2.15 | 1.59 | 2.18 | 0.73 | Upgrade
|
| Net Income | 6.6 | 5.31 | 9.68 | 9.09 | 8.06 | -13.01 | Upgrade
|
| Net Income to Common | 6.6 | 5.31 | 9.68 | 9.09 | 8.06 | -13.01 | Upgrade
|
| Net Income Growth | -33.63% | -45.17% | 6.53% | 12.79% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| EPS (Basic) | 2.75 | 2.21 | 4.03 | 3.79 | 3.36 | -5.42 | Upgrade
|
| EPS (Diluted) | 2.75 | 2.21 | 4.03 | 3.79 | 3.36 | -5.42 | Upgrade
|
| EPS Growth | -33.63% | -45.17% | 6.53% | 12.79% | - | - | Upgrade
|
| Free Cash Flow | 5.25 | -2.06 | -68.12 | -35.34 | -74.71 | -5.45 | Upgrade
|
| Free Cash Flow Per Share | 2.19 | -0.86 | -28.39 | -14.72 | -31.13 | -2.27 | Upgrade
|
| Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.500 | 1.000 | - | Upgrade
|
| Dividend Growth | - | - | -33.33% | 50.00% | - | - | Upgrade
|
| Gross Margin | 46.43% | 48.31% | 52.97% | 53.29% | 53.80% | 41.13% | Upgrade
|
| Operating Margin | 2.86% | 3.21% | 5.66% | 6.65% | 8.21% | -7.36% | Upgrade
|
| Profit Margin | 3.60% | 2.30% | 4.42% | 4.59% | 4.45% | -13.14% | Upgrade
|
| Free Cash Flow Margin | 2.86% | -0.89% | -31.06% | -17.84% | -41.28% | -5.51% | Upgrade
|
| EBITDA | 12.27 | 12.46 | 18.26 | 20.16 | 19.64 | -1.67 | Upgrade
|
| EBITDA Margin | 6.69% | 5.40% | 8.32% | 10.18% | 10.85% | -1.69% | Upgrade
|
| D&A For EBITDA | 7.02 | 5.07 | 5.84 | 6.99 | 4.79 | 5.61 | Upgrade
|
| EBIT | 5.25 | 7.39 | 12.41 | 13.17 | 14.86 | -7.28 | Upgrade
|
| EBIT Margin | 2.86% | 3.20% | 5.66% | 6.65% | 8.21% | -7.36% | Upgrade
|
| Effective Tax Rate | 24.96% | 27.26% | 18.16% | 14.90% | 21.25% | - | Upgrade
|
| Advertising Expenses | - | 0.82 | 1.12 | 1.43 | 4.58 | 0.93 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.